Single Agent Rituximab Active in Nodular Lymphocyte Predominant Hodgkin Lymphoma
b'This podcast describes the recent experience of single agent rituximab as management for newly diagnosed and relapsed nodular lymphocyte predominant Hodgkin lymphoma. The podcast includes a summary of the trial and discussion of the implications of the findings that rituximab has activity in both the upfront and relapsed setting.'